What's new?

Added 2 days ago Drug news

Completion of interim statistical assessment and small increase in target enrollment for KALM-2 phase III trial of Korsuva injection in hemodialysis patients with pruritus.- Cara Therapeutics

Cara Therapeutics, Inc. announced the completion of an interim statistical assessment of its pivotal KALM-2 Phase III global clinical trial...

Added 1 hour ago Drug news

Phase III REACH2 study of Jakafi meets endpoints in acute graft-versus-host disease.- Incyte

Incyte announced positive results from the Novartis-sponsored pivotal Phase III REACH2 study evaluating Jakafi (ruxolitinib) in patients with steroid-refractory acute...

Added 1 hour ago Drug news

Dovato filed with FDA in sNDA for adults with HIV-1 infection.- ViiV Healthcare

ViiV Healthcare announced the submission of a supplemental New Drug Application to the FDA for Dovato (dolutegravir and lamivudine) as...

Added 1 hour ago Drug news

Lilly announces phase III SEQUOIA study of pegilodecakin + FOLFOX in patients with metastatic pancreatic cancer did not meet primary endpoint of overall survival.

Eli Lilly and Company announced top-line results from its Phase III SEQUOIA trial evaluating pegilodecakin plus FOLFOX (folinic acid, 5-FU,...

Added 1 day ago Drug news

Positive topline results from the MOXIe registrational trial of omaveloxolone in patients with Friedreich’s ataxia.-

Reata Pharmaceuticals, Inc. announced that the registrational Part 2 portion of the MOXIe Phase II trial of omaveloxolone in patients...